Restrospective Study of Apalutamide, Darolutamide and Enzalutamide in Patients with Nonmetastatic, Castrate Resistant Prostate Cancer

[Survivor86]

jamanetwork.com/journals/ja...

While each of us responds differently to any prescribed drug, this new study reinforces the view that more nonmetastatic, castrate resistant prostate cancer patients may tolerate the side effects of darolutamide better compared to those taking enzalutamide or apalutamide and realize benefits in terms of delayed progression to metastatic disease. As summarized by the investigators:

“Findings In this cohort study of 870 patients with nmCRPC, darolutamide as initial ARI treatment was associated with significantly lower risks of discontinuation and progression to metastatic CRPC compared with enzalutamide and apalutamide, even after adjusting for patient baseline characteristics.”

“Meaning These findings suggest that darolutamide has a better tolerability profile compared with enzalutamide and apalutamide, which may be associated with an effectiveness advantage in routine clinical practice in men with nmCRPC.”